Resources for You
Combigan (brimonidine tartrate/timolol maleate) 0.2%/0.5% ophthalmic solution
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – October 2012
Neonates and Infants (Under the Age of 2 Years)
- Combiganis contraindicated in neonates and infants (under the age of 2 years).
WARNINGS AND PRECAUTIONS
- Ocular hypersensitivity reactions have been reported with brimonidine tartrate ophthalmic solutions 0.2%, with some reported to be associated with an increase in intraocular pressure.
- In infants, apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported.
- Symptoms of brimonidine overdose have been reported in neonates, infants, and children receiving brimonidine ophthalmic solutions as part of medical treatment of congenital glaucoma or by accidental oral ingestion.